Page last updated: 2024-10-15
myxin
Description
myxin: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 135452479 |
| CHEMBL ID | 4210631 |
| SCHEMBL ID | 29928 |
| MeSH ID | M0046652 |
Synonyms (27)
| Synonym |
|---|
| nsc-306757 |
| 3c antibiotic |
| myxin |
| 13925-12-7 |
| nsc306757 |
| 6-methoxy-1-phenazinol 5,10-dioxide |
| 1-hydroxy-6-methoxyphenazine 5,10-dioxide |
| 6-methoxy-5,10-dioxido-phenazine-5,10-diium-1-ol |
| 1-phenazinol, 6-methoxy-, 5,10-dioxide |
| brn 0622031 |
| nsc 306757 |
| 5-23-13-00363 (beilstein handbook reference) |
| qbe6kou32s , |
| unii-qbe6kou32s |
| 6-methoxy-phenazinol-5,10-dioxide |
| 6-methoxy-1-phenazinol-5,10-dioxide |
| myxin [mi] |
| SCHEMBL29928 |
| myxine |
| IMHLRMYGNZXFEO-UHFFFAOYSA-N |
| Q27287175 |
| CHEMBL4210631 |
| 6-methoxy-5,10-dioxidophenazine-5,10-diium-1-ol |
| HY-N10139 |
| DTXSID20865411 |
| 5-hydroxy-6-methoxy-10-oxo-10lambda~5~-phenazin-1(5h)-one |
| CS-0311351 |
Research Excerpts
Overview
Myxin is a well-known antibiotic that had been used for decades.
Bioassays (6)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1364438 | Antiproliferative activity against human MOLM13 cells after 24 hrs under 2% O2 condition by WST-1 assay | 2017 | Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
| Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives. |
| AID1726722 | Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by WST-1 assay | 2021 | RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
| New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells. |
| AID1364436 | Antiproliferative activity against human MOLM13 cells after 24 hrs under 19% O2 condition by WST-1 assay | 2017 | Bioorganic & medicinal chemistry, 04-01, Volume: 25, Issue:7
| Total synthesis and antileukemic evaluations of the phenazine 5,10-dioxide natural products iodinin, myxin and their derivatives. |
| AID1726731 | Effective permeability of the compound in PBS at 50 uM incubated for 5 hrs by PAMPA | 2021 | RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
| New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells. |
| AID1726725 | Cytotoxicity against rat H9c2 cells assessed as reduction in cell viability incubated for 24 hrs under 19% O2 condition by WST-1 assay | 2021 | RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
| New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells. |
| AID1726721 | Cytotoxicity against rat NRK cells assessed as reduction in cell viability incubated for 24 hrs under 2% O2 condition by WST-1 assay | 2021 | RSC medicinal chemistry, Apr-19, Volume: 12, Issue:5
| New prodrugs and analogs of the phenazine 5,10-dioxide natural products iodinin and myxin promote selective cytotoxicity towards human acute myeloid leukemia cells. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (6)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 1 (16.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 6 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |